Zepatier FDA Approval History
FDA Approved: Yes (First approved January 28, 2016)
Brand name: Zepatier
Generic name: elbasvir and grazoprevir
Dosage form: Tablets
Treatment for: Hepatitis C
Zepatier (elbasvir and grazoprevir) is a once-daily, single tablet, NS5A replication complex inhibitor and NS3/4A protease inhibitor combination for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections.
Development timeline for Zepatier
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.